🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Ken Fisher’s ALNY Holdings & Trades

First Buy
Q1 2026
Duration Held
1 Quarters
Largest Add
Q1 2026
+6,045 Shares
Current Position
6,045 Shares
$2 M Value

Ken Fisher's ALNY Position Overview

Ken Fisher (via Fisher Asset Management, LLC) currently holds 6,045 shares of Alnylam Pharmaceuticals, Inc. (ALNY) worth $2 M, representing 0.00% of the portfolio. First purchased in 2026-Q1, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Ken Fisher has initiated a new position in ALNY, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Ken Fisher's Alnylam Pharmaceuticals (ALNY) Holding Value Over Time

Track share changes against reported price movement

Quarterly Alnylam Pharmaceuticals (ALNY) Trades by Ken Fisher

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q1 2026 +6,045 New Buy 6,045 $330.91

Ken Fisher's Alnylam Pharmaceuticals Investment FAQs

Ken Fisher first purchased Alnylam Pharmaceuticals, Inc. (ALNY) in Q1 2026, acquiring 6,045 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ken Fisher has held Alnylam Pharmaceuticals, Inc. (ALNY) for 1 quarters since Q1 2026.

Ken Fisher's largest addition to Alnylam Pharmaceuticals, Inc. (ALNY) was in Q1 2026, adding 6,045 shares worth $2 M.

According to the latest 13F filing for Q1 2026, Ken Fisher's firm, Fisher Asset Management, LLC, owns 6,045 shares of Alnylam Pharmaceuticals, Inc. (ALNY), valued at approximately $2 M.

As of the Q1 2026 filing, Alnylam Pharmaceuticals, Inc. (ALNY) represents approximately 0.00% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings.

Ken Fisher's peak holding in Alnylam Pharmaceuticals, Inc. (ALNY) was 6,045 shares, as reported at the end of Q1 2026.